Vanda Pharmaceuticals Inc. (VNDA) Form 10-K Annual Reports
Vanda Pharmaceuticals Inc. (VNDA) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: VNDA
CIK: 1347178
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerDavid Woodall
Audit LocationWashington, District of Columbia, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G/A | 2026-10-09 | — | SCHEDULE 13G/A Filing | 0001104659-26-115112 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-19 | — | SCHEDULE 13G Filing | 0001104659-26-098866 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-13 | — | SCHEDULE 13G Filing | 0001167557-26-000170 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001628280-26-053855 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | 8-K | 0001628280-26-053308 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261871 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261811 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261806 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261800 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261790 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261782 | View SEC Doc Filr Page |
| 4 | 2026-06-08 | 2026-06-04 | 4 | 0001193125-26-261768 | View SEC Doc Filr Page |
| 3 | 2026-06-08 | 2026-06-04 | 3 | 0001193125-26-261752 | View SEC Doc Filr Page |
| S-8 | 2026-06-05 | — | S-8 | 0001628280-26-041303 | View SEC Doc Filr Page |
| 8-K | 2026-06-05 | 2026-06-04 | 8-K | 0001628280-26-041298 | View SEC Doc Filr Page |
| 4 | 2026-05-20 | 2026-05-18 | 4 | 0001802653-26-000003 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-12 | — | SCHEDULE 13G Filing | 0000093751-26-000309 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | 10-Q | 0001628280-26-031667 | View SEC Doc Filr Page |
| 8-K | 2026-05-06 | 2026-05-06 | 8-K | 0001628280-26-031241 | View SEC Doc Filr Page |
| EFFECT | 2026-05-05 | — | EFFECT Filing | 9999999995-26-001496 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-04-29 | — | SCHEDULE 13G/A Filing | 0002052113-26-000465 | View SEC Doc Filr Page |
| CORRESP | 2026-04-24 | — | CORRESP Filing | 0001193125-26-177526 | View SEC Doc Filr Page |
| 4 | 2026-04-24 | 2026-04-22 | 4 | 0002130896-26-000008 | View SEC Doc Filr Page |
| 3 | 2026-04-24 | 2026-04-22 | 3 | 0002130896-26-000006 | View SEC Doc Filr Page |
| ARS | 2026-04-23 | 2025-12-31 | ARS | 0001628280-26-026899 | View SEC Doc Filr Page |